Nuvation Bio to expand pivotal Phase 3 Sigma study of safusidenib for IDH1-mutant glioma to six European countries
NUVB•Nuvation Bio will expand its pivotal Phase 3 Sigma study of safusidenib for IDH1-mutant glioma to six European countries.
1. Study expansion
Nuvation Bio will expand its pivotal Phase 3 Sigma study of safusidenib for IDH1-mutant glioma to six European countries.
